Alvotech ends Jefferies ATM prospectus supplement

Alvotech has suspended and terminated its ATM Prospectus Supplement with Jefferies LLC, which had allowed potential open market issuances of its ordinary shares under an Open Market Sale agreement dated June 14, 2024.

Accepted by SEC EDGAR 06/15/2026 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Alvotech has suspended and terminated its ATM Prospectus Supplement with Jefferies LLC, which had allowed potential open market issuances of its ordinary shares under an Open Market Sale agreement dated June 14, 2024. The underlying Sales Agreement remains in effect, but the company will not sell securities under it unless a new prospectus supplement or a new registration statement is filed.

Key Terms

ATM Prospectus Supplement, Open Market Sale, Form F-3ASR, registration statement on Form S-8

4 terms

ATM Prospectus Supplement financial

"it was suspending its use of and terminating the prospectus supplement (the “ATM Prospectus Supplement”)"

An at-the-market (ATM) prospectus supplement is a legal update that lets a company sell new shares directly into the open market over time using an existing registration document. Think of it like an add-on permission that allows gradual stock sales instead of one big offering; investors watch it because ongoing share sales can increase supply, dilute existing holdings, and affect the stock price and company funding plans.

Open Market Sale financial

"ordinary shares pursuant to the Open Market Sale , dated June 14, 2024"

An open market sale is when a company or a shareholder sells shares through the regular stock market to any willing buyer, using ordinary exchange trading rather than private deals. It matters to investors because it increases the number of shares available and can push the price down or change ownership balance—think of it like someone putting extra items on a supermarket shelf for any shopper to buy, which can lower the item's price if supply suddenly grows.

Form F-3ASR regulatory

"the Company’s registration statement on Form F-3ASR (File No. 333-289006)"

Form F-3ASR is a U.S. Securities and Exchange Commission filing that lets an eligible foreign company pre-register securities for sale to U.S. investors using the SEC’s automatic shelf process. Think of it like a pre-approved credit line: it gives the company the flexibility to raise money quickly when needed, which matters to investors because it can speed new share or bond offerings, affect supply of securities, and therefore influence share price and dilution risk.

registration statement on Form S-8 regulatory

"the Company’s registration statement on Form S-8 (File No. 333-266881)"

A registration statement on Form S-8 is the U.S. Securities and Exchange Commission filing companies use to register shares they intend to grant to employees, directors, consultants or benefit plans under stock compensation programs. It matters to investors because it signals potential issuance of new shares tied to pay and incentives, which can increase the total shares outstanding — like adding more slices to a pie — reducing each existing share’s ownership and potentially affecting earnings per share and stock value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alvotech (ALVO) change regarding its ATM program with Jefferies?

Alvotech suspended and terminated its ATM Prospectus Supplement with Jefferies LLC. This supplement had allowed potential open market issuances of ordinary shares under an existing Sales Agreement dated June 14, 2024.

Can Alvotech (ALVO) still sell shares under the Jefferies Sales Agreement?

Alvotech will not sell securities under the Jefferies Sales Agreement unless a new prospectus supplement or a new registration statement is filed. The Sales Agreement itself remains in full force and effect despite the supplement’s termination.

Does the termination affect Alvotech’s Sales Agreement with Jefferies?

The termination only affects the ATM Prospectus Supplement, not the Sales Agreement. The filing states that, other than ending the ATM Prospectus Supplement, the Sales Agreement between Alvotech and Jefferies LLC remains in full force and effect.

Which Alvotech registration statements incorporate this 6-K by reference?

This report is incorporated by reference into Alvotech’s Form F-3 registration statements (File Nos. 333-266136, 333-273262, 333-275111, 333-281684), its Form F-3ASR registration statement (File No. 333-289006), and its Form S-8 registration statement (File No. 333-266881).

Who signed the Alvotech Form 6-K regarding the ATM prospectus termination?

The Form 6-K was signed on behalf of Alvotech by Tanya Zharov. She signed the report as General Counsel of the company, dated June 15, 2026, in accordance with Securities Exchange Act requirements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of June 2026

Commission File Number: 001-41421

Alvotech

(Translation of registrant’s name into English)

9, Rue de Bitbourg,

L-1273 Luxembourg,

Grand Duchy of Luxembourg

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒  Form 20-F    ☐  Form 40-F

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Termination of ATM Prospectus Supplement

On June 15, 2026, the Company notified Jefferies LLC that it was suspending its use of and terminating the prospectus supplement (the “ATM Prospectus Supplement”), related to the potential issuance from time to time of the Company’s ordinary shares pursuant to the Open Market Sale Agreement^SM, dated June 14, 2024, by and between the Company and Jefferies LLC (the “Sales Agreement”). The Company will not make any sales of its securities pursuant to the Sales Agreement unless and until a new prospectus supplement or a new registration statement is filed. Other than the termination of the ATM Prospectus Supplement, the Sales Agreement remains in full force and effect.

INCORPORATION BY REFERENCE

This Report shall be deemed to be incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-266136, 333-273262, 333-275111, and 333-281684), the Company’s registration statement on Form F-3ASR (File No. 333-289006), and the Company’s registration statement on Form S-8 (File No. 333-266881), including any prospectuses forming a part of such registration statements, and to be a part thereof from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		ALVOTECH
Date:	June 15, 2026	By:	/s/ Tanya Zharov
			Name:	Tanya Zharov
			Title:	General Counsel